NovoCure Aktie

10,52 EUR +1,69 EUR +19,14 %

12.02.2026

BMN

12,44 USD -0,11 USD -0,84 %

nachbörslich01:40:33

BTT

NovoCure jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.990,49 Mio. EUR

Div. Rendite0,00%

WKNA140ML

ISINJE00BYSS4X48

SymbolNVCR

NovoCure Aktien News

Sortieren:Datum Meistgelesen

21.11.24BusinesswireNovocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

21.11.24BusinesswireFDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

30.10.24BusinesswireNovocure Appoints Christoph Brackmann as Chief Financial Officer

30.10.24BusinesswireNovocure Reports Third Quarter 2024 Financial Results

15.10.24BusinesswireFDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

01.10.24BusinesswireNovocure to Report Third Quarter 2024 Financial Results

09.09.24BusinesswireNovocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

03.09.24BusinesswireNovocure Announces Planned CEO Transition

28.08.24BusinesswireNovocure to Participate in 2024 Wells Fargo Healthcare Conference

14.08.24BusinesswireNovocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

25.07.24BusinesswireNovocure Reports Second Quarter 2024 Financial Results

01.07.24BusinesswireNovocure to Report Second Quarter 2024 Financial Results

03.06.24BusinesswireMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

02.05.24BusinesswireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

02.05.24BusinesswireNovocure Reports First Quarter 2024 Financial Results

01.04.24BusinesswireNovocure to Report First Quarter 2024 Financial Results

11.03.24BusinesswireINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

22.02.24BusinesswireNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

18.01.24BusinesswireNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

09.01.24BusinesswireNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

08.01.24BusinesswireNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

04.01.24BusinesswireNovocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

27.12.23BusinesswireNovocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

28.11.23BusinesswireNovocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

21.11.23BusinesswireNovocure to Participate in 35th Annual Piper Sandler Healthcare Conference

10.11.23BusinesswireNovocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

26.10.23BusinesswireNovocure Reports Third Quarter 2023 Financial Results

16.10.23BusinesswireNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

12.10.23BusinesswireNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

29.09.23BusinesswireNovocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

08.09.23BusinesswireNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

30.08.23BusinesswireNovocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

28.08.23BusinesswireNovocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

25.08.23BusinesswireNovocure to Participate in Upcoming Investor Conferences

15.08.23PR NewswireNVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders

11.08.23PR NewswireNVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit

10.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

10.08.23PR NewswireNVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

10.08.23PR NewswireNVCR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR

04.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NovoCure News

NovoCure News: auf dieser Seite finden Sie alle NovoCure News und Nachrichten zur NovoCure Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NovoCure News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NovoCure News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.